In this paper, we investigate a previously proposed mathematical model describing the effects that an innovative combined radiopharmaceutical therapy might have on the delivery of radiation to the tumor and limiting critical organs. While focused on a specific dual agent therapy, this investigation will prove mathematically that for any two therapeutic radiopharmaceuticals with different limiting critical organs the model provides patient specific conditions under which combination therapy is superior to single agent therapy. In addition, this paper outlines general methods for calculating the amounts of administered radioactivity for each drug required to optimize tumor radiation dose. We also consider extensions of this model to include an arbitrary number of independent radiopharmaceuticals and/or other treatment factors.
FeldmanM.ScharschmidtB.SleisengerM.FordtranJ. in Gastrointestinal and Liver Diseases, W. B. Saunders, Philadelphia, PA (1998).
2.
MatthayK.Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acit, Children's Cancer Group. N Engl J Med341, 1165–1173 (1999).
3.
McDermottE.SuduricB.BrennanM.Prognostic variables in patients with gastrointestinal carcinoid tumors. Br J Surg81, 1007–1009 (1994).
4.
WaldherrC.Tumor Response and Clinical Benefit in Neuroendocrine Tumors After 7.4 GBq 90 Y-DOTATOC. J Nucl Med43, 610–616 (2002).
5.
OtteA.Yttrium-90 DOTATOC: First clinical results. Euro J Nucl Med26, 1439–1447 (1999).
6.
TeunissenJ.KwekkeboomD.KrenningE., Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [177 Lu-DOTA0, Tyr3] octreotate. J Clin Oncology22, 2724–2729 (2004).
7.
LashfordL.Phase I/II Study of Iodine 131 Metaiodobenzylguanidine in Chemoresistant Neuroblastoma: A United Kingdom Children's Cancer Study Group Investigation. J Clinical Oncology10, 1889–1896 (1992).
8.
BushnellD.Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors. J Gastrointest Surg10, 335–336 (2006).
9.
KangT.Targeted Radiotherapy With Submyeloblative Doses of 131 I-MIBG IS Effective for Disease Palliation in Highly Refractory Neuroblastoma. Pediatr Hematol Oncol25, 769–773 (2003).
10.
BreemanW.Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. Euro J Nucl Med28, 1421–1429 (2001).
11.
JongM.KwekkeboomD.ValkemaR.KrenningE.Radiolabeled peptides for tumor therapy: Current status and future directions. Euro J Nucl Med30, 463–469 (2003).
12.
KwekkeboonD.Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs. J Nucl Med46 (suppl), 62–66 (2005).
13.
NguyenC.Long-Term Efficacy of Radionuclide Therapy in Patients with Disseminated Neuroendocrine Tumors Uncontrolled by Conventional Therapy. J Nucl Med45, 1660–1668 (2004).
14.
SaffordS.Iodine-131 Metaiodobenzylguanidine Treatment for Metastatic Carcinoid. Cancer1, 1987–1993 (2004).
15.
LewingtonV.Targeted radionuclide therapy for neuroendocrine tumors. Endocrine-Related Cancer10, 497–501 (2003).
16.
HowardJ.Tumor response and Toxicity with Multiple Infusions of High Dose 131 I-MIBG for Refractory Neuroblastoma. Pediatr Blood & Cancer44, 232–239 (2005).
17.
BomanjiJ.Treatment of Neuroendocrine Tumors in Adults with 131 I-MIBG Therapy. Clinical Oncology15, 193–198 (2003).
18.
MatthayK.Correlation of Tumor and Whole-Body Dosimetry with Tumor Response and Toxicity in Refractory Neuroblastoma Treated with 131 I-MIBG. J Nucl Med42, 1713–1721 (2001).
19.
TronconeL.RufiniV.RiccardiR.LasorellaA.MastrangeloR.The use of [131I] metaiodobenzylguanidine in the treatment of neuroblastoma after conventional therapy. J Nucl Biol Med35, 232–236 (1991).
20.
PauwelsS.Practical Dosimetry of Peptide Receptor Radionuclide Therapy with 90 Y-Labeled Somatostatin Analogs. J Nucl Med46 (suppl), 92–98 (2005).
21.
SignoreA.Peptide radiopharmaceuticals for diagnosis and therapy. Euro J Nucl Med28, 1555–1565 (2001).
22.
ReubiJ.MackeH.KrenningE.Candidates for Peptide Receptor Radiotherapy Today and in the Future. J Nucl Med46 (Suppl), 67–75 (2005).
23.
MoyesJ.Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: Correlation with tumor histopathology. J Nucl Med30, 474–480 (1989).
24.
SyedG. ShahNaseer, H., Usmani, G., Cheema, M. Role of Iodine-131 MIBG Scanning in the Management of Paediatric Patients with Neuroblastoma. Med Princ Pract13, 196–200 (2004).
25.
BomanjiJ.LevisonD. A.FlatmanW. D.HorneT.BoulouxP. M.-G.RossG.BrittonK. E.BesserG. M.Uptake of Iodine-123 MIBG by Pheochromocytomas, Paragangliomas, and Neuroblastomas: A Histopathological Comparison. J Nucl Med28, 973–978 (1987).
26.
WafelmanA.HoefnagelC.MaesR.BeijnenJ.Radioiodinated metaiodobenzylguanidine: A review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and Dosimetry. Euro J Nucl Med21, 545–559 (1994).
27.
de JongM.Somatostatin Receptor-Targeted Radionuclide Therapy of Tumors: Preclinical and Clinical Findings. Seminars in Nuclear MedicineXXXII, 133–140 (2002).
28.
MadsenM.BushnellD.MendaY.O'DorisioT.Potential Therapeutic Advantage with Combined I-131 MIBG and Y-90 Dota-D-Phe1-Tyr3-Octrotide (Dotatoc) for Treating Neuroendocrine Tumors. J Nucl Med46 (Suppl), 448 (2005).
29.
MadsenM.Potential increased tumor dose delivery with combined I-131 MIBG and Y-90 DOTATOC treatment in neuroendocrine tumors: A theoretic model. J Nucl Med47, 660–667 (2006).
30.
VanderbeiR. in Linear Programming: Foundations and Extensions, 2nd ed.Springer International Series, New York, NY (2001).
31.
TaalB.HoefnagelC.OlmosR. ValdesBootH.Combined Diagnostic Imaging with 131 I-Metaiodobenzylguanidine and 111 In-Pentet-reotide in Carcinoid Tumors. Euro J Cancer32A, 1924–1932 (1996).
32.
KaltsasG.Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors. J Clin Endocrinol Metab86, 895–902 (2001).
33.
Le RestC.Functional imaging of malignant Paragangliomas and carcinoid tumours. Euro J Nucl Med28, 478–482 (2001).
34.
QuigleyA.BuscombeJ.GopinathG.CaplinM.HilsonA.In-Vivo Characterization of the Functional Aspects of Carcinoid Tumors by Imaging Somatostatin Receptors and Amine Uptake. J Nucl Med44 (suppl), 74P (2003).
35.
MiceliA.NespoliL.AprilsC.BurgioG.VMA-negative, MIBG scan-positive neuroblastoma in children. Euro J Pediatr145, 325 (1986).
36.
SiegelJ.StabinM.Absorbed fractions for electrons and beta particles on spheres of various sizes. J Nucl Med35, 152–156 (1994).
37.
O'DonoghueJ.BardiesM.WheldonT.Relationship between tumor size and curability for uniformly targeted therapy with beta emitting radionuclides. J Nucl Med36, 1902–1909 (1995).
38.
GazeM.MairsR.BoyackS.WheldonT.BarrettA.131 I-metaiodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer66, 1048–1052 (1992).
